BiomX Announces Positive Phase 2 Results for BX211 in Diabetic Foot Osteomyelitis

BiomX Inc.

BX211 showed statistically significant ulcer size reduction (PAR) at week 12 (p=0.046) and week 13 (p=0.052) vs placebo.
BX211 reduced ulcer depth (p=0.048) and limited ulcer area expansion (p=0.017) compared to placebo.
Phase 2 trial enrolled 41 patients (26 BX211, 15 placebo) with DFO associated with S. aureus; BX211 safe and well-tolerated.
BiomX plans Phase 2/3 trial pending FDA feedback; KOL event scheduled April 3, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.